Real World Data to Provide Real World Evidence

• 6632 · PDF 2000年至2020年美国胶质母细胞瘤患者治疗与生存趋势：一项基于人群的SEER分析 Trends in treatment and survival among patients with glioblastoma in the United States, 2000 to 2020: A population-based SEER analysis Jianan Chen, Qiong Wu, Catherine Boldig, Rob J B Macaulay, Arnold Etame
• 6633 · PDF PD-L1表达依赖的一线免疫检查点抑制剂联合化疗在晚期胃癌及胃食管结合部腺癌中的疗效：III期临床试验的系统评价与荟萃分析 PD-L1 expression-dependent efficacy of first-line immune checkpoint inhibitor plus chemotherapy in advanced gastric and gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis of phase III trials Jialun Lyu, Zhenzhen Zhang, Krishnapriya Thangaretnam, Md Obaidul Islam, Jason Tang, Sabine Denize, Nadeem Bhat, Shoumin Zhu, Heng Lu, Dunfa Peng, Wael El Rifai, Zheng Chen
• 6634 · PDF nivolumab + ipilimumab与atezolizumab + bevacizumab治疗晚期肝细胞癌的真实世界比较结局：一项TRINETX研究 Real-world comparative outcomes of nivolumab + ipilimumab vs. atezolizumab + bevacizumab in advanced hepatocellular carcinoma: A TRINETX study Sameh Gomaa, Abdelrahman Omara, Hatem Ahmed, Imad Alabdul Razzak, Potdar Rashmika, Kuang-Yi Wen
• 6635 · PDF 利用大型国家癌症数据库评估累及肝脏和胃肠道的IV期PTCL, NOS Evaluation of stage IV PTCL, NOS of the liver and gastrointestinal tract using a large national cancer database Olivia Davis, Taha Al-Juhaishi, Ryan Wilcox
• 6636 6636 基于原发部位的IV期黏液腺癌临床结局 Clinical outcomes of stage IV mucinous adenocarcinoma based on primary sites Wongi Woo, Seoin Kim, Jongwoo Kim, Vincent Lopez, Yeena Lee, Kirun Chohan, Young Kwang Chae
• 6637 · PDF KRAS G12D突变非小细胞肺癌患者的真实世界结局：加州大学健康数据仓库回顾性分析 Real world outcomes for patients with KRAS G12D -mutated non-small cell lung cancer: A University of California Health Data Warehouse retrospective analysis Jingtong Liang, Tali Azenkot, Sandip Patel
• 6638 · PDF eflapegrastim（efla）在胃肠道（GI）恶性肿瘤患者中应用的真实世界证据 Real-World evidence of eflapegrastim (efla) usage in patients with gastrointestinal (GI) malignancies Howard Franklin, Jeffrey Crawford, John H. Baird, Kenneth Crist, Vincent Marino, Neil Shah, Lee S. Schwartzberg
• 6639 · PDF 既往心脏病对胰腺癌生存和术后结局的影响：一项TriNetX分析 Impact of preexisting heart disease on survival and postoperative outcomes in pancreatic cancer: A TriNetX analysis Charlotte Burch, Jacob Lambdin, William Royster, Adam Khader, Leopoldo Fernandez, Raphael Louie, Ricardo Bello, Jose G. Trevino
• 6640 · PDF 诊断时的老年营养风险指数可预测胰腺癌生存 Geriatric nutritional risk index at diagnosis predicts survival in pancreatic cancer Christina Grinstead, Saunjoo Yoon
• 6642 · PDF 胰腺癌化疗反应的代谢预测因子 Metabolic predictors of chemotherapy response in pancreatic cancer Parnian Naji, Jordan Winter
• 6643 · PDF ER-low乳腺癌脑转移的发生率与结局：来自美国国家癌症数据库（NCDB）的见解 Incidence and outcomes of brain metastasis in ER-low breast cancer: Insights from a National Cancer Database (NCDB) Aanika B. Warner, Sarah Darmon, Jeremy Perkins, Matt Nealeigh, Craig D. Shriver, Stan Lipkowitz, Kangmin Zhu, Takeo Fujii
• 6644 · PDF 辅助剂量密集化疗与早期、淋巴结阴性、HER2阴性乳腺癌无复发生存期的改善无关 Adjuvant dose-dense chemotherapy is not associated with improved recurrence-free survival in early-stage, node-negative, HER2-negative breast cancer Jonathan Shpigelman, Tasnem Alsebai, Kathy Robinson, Aum Nimavat, Ricardo Cossyleon, Krishna Rao
• 6645 · PDF 影响新辅助化疗后有残留病灶的三阴性乳腺癌患者辅助卡培他滨相对剂量强度的实践模式 Practice patterns impacting relative dose intensity of adjuvant capecitabine among triple negative breast cancer patients with residual disease following neoadjuvant chemotherapy Andrea House, Pratik Thakur, Blair Hoeting, Ruth Johnson, Brittany Sandoval, Julie Stephens, Daniel G. Stover, Sagar Sardesai, Tanun Jitwatcharakomol, Sasha Beyer, Arya M. Roy, Nerea Lopetegui-Lia, Dionisia M. Quiroga, Ashley P. Davenport, Gilbert Bader, Nicole O. Williams, Robert Wesolowski, Margaret E. Gatti-Mays, Kai C. C. Johnson
• 6646 · PDF 组织学亚型（导管、小叶和混合导管/小叶）对雌激素受体低（ER-low）HER2阴性乳腺癌新辅助化疗（NAC）和化疗免疫治疗（NACI）后病理完全缓解（pCR）的影响 Impact of histology subtypes (ductal, lobular, and mixed ductal/lobular) on pathological complete response (pCR) following neoadjuvant chemotherapy (NAC) and chemoimmunotherapy (NACI) for estrogen receptor low (ER-low) HER2-negative breast cancer Kai C. C. Johnson, Brandon Slover, Yengeniya Gokun, Dionisia M. Quiroga, Sagar Sardesai, Sachin Jhawar, Nerea Lopetegui-Lia, Arya M. Roy, Gilbert Bader, Ashley P. Davenport, Nicole O. Williams, Robert Wesolowski, Margaret E. Gatti-Mays, Daniel G. Stover
• 6647 6647 MCM2与复制起点许可复合物：ER+/HER2-乳腺癌治疗耐药的一个假定节点 MCM2 and the origin licensing complex: A putative node of ER+/HER2- breast cancer therapy resistance Alekya Raghavan, Rosemary N. Plagens, Cynthia X. Ma, Stephanie Graff, Maryam Lustberg, Andrew Elliott, George W. Sledge, C. Kent Osborne, Mothaffar F. Rimawi, Ahmed Elkhanany, Rachel Schiff
• 6648 · PDF HR+/HER2-乳腺癌中区域剥夺指数（ADI）与CDK4/6抑制剂（CDK4/6i）治疗持续性（TP）之间的关联 Association between area deprivation index (ADI) and treatment persistence (TP) with CDK4/6 inhibitors (CDK4/6i)in HR+/HER2- breast cancer Michelle L. Caetano, Jessica Liu, Britny R. Brown, Guannan Gong, Sameer Pandya, Salma Taghzout, Mariah Ramos, Edward Tupper, Annette Hood, Michael Zummo, Robert Legare, Jing Du, Maryam Lustberg
• 6649 6649 转移性非小细胞肺癌继发性中枢神经系统转移的比较风险：在TriNetX上进行的pembrolizumab与atezolizumab单药治疗的真实世界倾向性匹配分析 Comparative risk of secondary central nervous system metastases in metastatic non-small cell lung cancer: A real-world propensity-matched analysis of pembrolizumab vs atezolizumab monotherapy conducted on TriNetX Umer Rizwan, Athar Nawab, Syed Najafi, Karandeep Bawa, Fnu Muhibullah, Christian Kaftanic, Sunanda Tah, Sabir Hussain
• 6650 · PDF belzutifan治疗Von Hippel-Lindau病相关肿瘤的安全性和疗效 Safety and efficacy of belzutifan for Von Hippel-Lindau disease-associated tumors Peixi Ge, Mohamed Atta, Nityasree Srialluri
• 6651 · PDF T细胞衔接器在多发性骨髓瘤中的感染风险特征 Characterizing the risk of infections with T-cell engagers in multiple myeloma Lindsay Fogel, Harsh Parmar, Shucen Wan, Adolfo Aleman, Pooja Phull, David Vesole, David S. Siegel, Rena Feinman, Claire L. Carter, Noa Biran
• 6652 · PDF 病毒性肝炎悖论：老年HCC移植患者预后更佳 Viral hepatitis paradox: Better outcomes in geriatric HCC transplant patients Ewan Kim, Sungsu Park, Amy Choi
• 6653 · PDF 肝脾T细胞淋巴瘤gamma-delta型与alpha-beta型：临床病理特征和结局的比较研究 Hepatosplenic T-cell lymphoma gamma-delta versus alpha-beta: A comparative study of clinicopathologic features and outcomes Philip A. Haddad, Sireesha Vutukuri, Ankita Gupta
• 6654 · PDF 评估系统性硬化症合并器官移植患者的皮肤癌风险：一项队列研究 Assessing skin cancer risk in systemic sclerosis patients with organ transplantation: A cohort study Ruhi Kanwar, Ellen Anshelevich, Goranit Sakunchotpanit, Kevin Fettel, Vinod E. Nambudiri
• 6655 · PDF 慢性髓性白血病患者使用ponatinib、bosutinib和asciminib情况下皮肤不良反应的特征 Characterization of adverse cutaneous effects in the setting of ponatinib, bosutinib, andasciminib for chronic myeloid leukemia patients Ruhi Kanwar, Juna Khang, Goranit Sakunchotpanit, Ruhi Nayak, Nicole R. LeBoeuf, Vinod E. Nambudiri

在会议检索中浏览本分会场